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Abstract: Mortality rates attributable to coronary heart disease have declined in recent years, 
possibly related to changes in clinical presentation patterns and use of proven secondary preven-
tion strategies. Chronic stable angina (CSA) remains prevalent, and the goal of treatment is control 
of symptoms and reduction in cardiovascular events. Ranolazine is a selective inhibitor of the 
late sodium current in myocytes with anti-ischemic and metabolic properties. It was approved 
by the US Food and Drug Administration in 2006 for use in patients with CSA. Multiple, ran-
domized, placebo-controlled trials have shown that ranolazine improves functional capacity and 
decreases anginal episodes in CSA patients, despite a lack of a significant hemodynamic effect. 
Ranolazine did not improve cardiovascular mortality or affect incidence of myocardial infarction 
in the MERLIN (Metabolic Efficiency with Ranolazine for  Less Ischemia in Non-ST-Elevation 
Acute Coronary Syndrome)-TIMI (Thrombolysis In Myocardial Infarction) 36 trial, but signifi-
cantly decreased the incidence of recurrent angina. More recently, ranolazine has been shown 
to have beneficial and potent antiarrhythmic effects, both on supraventricular and ventricular 
tachyarrhythmias, largely due to its inhibition of the late sodium current. Randomized controlled 
trials testing these effects are underway. Lastly, ranolazine appears to be cost-effective due to its 
ability to decrease angina-related hospitalizations and improve quality of life.
Keywords: ranolazine, chronic stable angina, coronary artery disease
Introduction
Mortality rates attributable to cardiovascular disease have declined in recent decades, 
but the burden of disease remains high. From 1999 to 2009, the relative rate of death 
attributable to cardiovascular disease declined by 32.7%. However, in 2009, cardio-
vascular disease still accounted for 32.3% of all deaths, or one in every three deaths 
in the USA.1
According to the most recent data published by the American Heart Association, 
coronary heart disease (CHD) alone caused approximately one of every six deaths in the 
USA in 2009. On the basis of data from the National Health and Nutrition Examination 
Survey 2007–2010, an estimated 15.4 million Americans have CHD, with a prevalence 
of 6.4% in the US population. From 1999 to 2009, the annual death rate attributable 
to CHD declined by 40.3% and the actual number of deaths declined by 27.1%.2 The 
decline in CHD deaths partly reflects a shift in the pattern of clinical presentation of 
acute myocardial infarction. In the past decade, there has been a marked decline in 
ST-segment elevation myocardial infarction.3 Further, after 1980 and 2000 data were 
compared, it was estimated that approximately 47% of the decrease in CHD deaths was 
attributable to treatments, including secondary preventive therapies, initial treatment 
after acute myocardial infarction, and revascularization for chronic angina.4
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Angina pectoris, ie, chest pain or discomfort that results 
from insufficient blood flow to the heart muscle, was accu-
rately reported by William Heberden in 1772.5 Chronic stable 
angina (CSA) is usually described as predictable chest pain 
on exertion or when under mental or emotional stress. Only 
18% of acute coronary syndromes are preceded by longstand-
ing CSA. Estimates from the National Health and Nutrition 
Examination Survey 2007–2010 show a prevalence of CSA 
of 7.8 million people (3.2% of the US population). The 
annual rates per 1,000 population of new episodes of CSA for 
nonblack men are 28.3 for those aged 65–74 years, 36.3 for 
those aged 75–84 years, and 33.0 for those aged $85 years. 
For nonblack women in the same age groups, the rates are 
14.1, 20.0, and 22.9, respectively. For black men, the rates 
are 22.4, 33.8, and 39.5, and for black women, the rates are 
15.3, 23.6, and 35.9, respectively.6
The two aims of pharmacological management for 
CSA are to obtain relief of symptoms and to prevent 
cardiovascular events. These are usually achieved by phar-
macological or lifestyle interventions that reduce plaque 
progression,  stabilize plaque by reducing inflammation, 
and prevent thrombosis, should plaque rupture or erosion 
occur.
First-line treatment is indicated with beta-blockers and/or 
calcium channel blockers to control heart rate and  symptoms, 
as well as nitrates for symptomatic relief.  Prevention of 
cardiovascular events is usually accomplished by use of anti-
platelet agents, statins, and possibly angiotensin-converting 
enzyme inhibitors or angiotensin II receptor antagonists. 
Coronary revascularization generally improves survival 
among certain subgroups of patients, particularly those with 
severe left main coronary stenosis.7 Ranolazine is a novel 
agent with anti-ischemic and metabolic properties, and was 
approved by the US Food and Drug Administration in 2006 
for the treatment of patients with CSA.8
Overview of pharmacology  
of ranolazine
Ranolazine is a selective inhibitor of the late sodium  current 
(INaL) in cardiomyocytes and has anti-ischemic and meta-
bolic properties. Its extended-release (ER) form was approved 
in doses of 500 mg twice daily and 1,000 mg twice daily, 
based on clinical symptoms. After oral administration, peak 
plasma concentrations of ranolazine are reached between 
2 and 5 hours. Ranolazine is extensively metabolized in 
the gut and liver, and its absorption is highly variable. 
The elimination half-life of ranolazine is 1.4–1.9 hours, 
but is apparently prolonged, on average, to 7 hours for 
the ER formulation as a result of extended absorption 
 (flip-flop kinetics). Steady state is generally achieved within 
3 days of twice-daily dosing.9,10
The drug is metabolized mainly by cytochrome P450 
(CYP) 3A4 and, to a lesser extent, by CYP2D6. This occurs 
rapidly and extensively in the liver and intestine; less than 
5% is excreted unchanged in urine and feces.9 Ranolazine is 
a weak inhibitor of CYP3A4 and CYP2D6. The interactions 
of ranolazine with inhibitors and substrates of the CYP3 
family have been studied.11 Ketoconazole was associated 
with the largest effect, increasing the area under the plasma 
concentration time curve of ranolazine by 3.9-fold, followed 
by diltiazem (1.5-fold), whereas simvastatin was too weak 
an inhibitor to significantly affect the pharmacokinetic 
parameters of ranolazine. Further, ranolazine is a substrate 
for and transported by P-glycoprotein. Verapamil is a potent 
P-glycoprotein inhibitor and also inhibits CYP3A4, and 
can lead to a 2–3-fold increase in the area under plasma 
concentration time curve for ranolazine.9 Concomitant use 
of ranolazine and drugs transported by P-glycoprotein (such 
as digoxin) results in increased exposure to the latter and the 
dose may have to be adjusted.
Ranolazine is contraindicated in patients receiving strong 
CYP3A4 inhibitors or inducers and those with liver cirrhosis. 
It is also recommended to limit the dose to 500 mg daily in 
those receiving moderate CYP3A4 inhibitors, (diltiazem, 
verapamil, erythromycin), and to limit the dose of simvastatin 
to 20 mg when used in combination with ranolazine.10
Inhibition of the rapidly activating delayed rectifier 
potassium current (IKr) by ranolazine explains the effect 
of the drug to prolong ventricular and atrial action potential 
duration, as well as the small QTc interval prolongation 
observed in clinical trials. Despite this effect, ranolazine 
does not induce torsades de pointes and possibly suppresses 
long QT-related ventricular arrhythmias, as shown in long 
QT experimental trials.12,13
The antianginal mechanism of action of ranolazine has 
not been fully elucidated. Initial studies proposed myocar-
dial metabolic modulation as the predominant mechanism 
of action, with minimal or no effect on heart rate, coronary 
blood flow, and systemic arterial blood pressure.14 In the 
healthy heart, fatty acids are the primary fuel source for 
the generation of adenosine triphosphate (ATP).15 During 
ischemia, fatty acid and pyruvate oxidation both decrease 
as  glycolysis becomes the predominant route for ATP 
production.  Glycolytic regeneration of ATP leads to intracel-
lular acidosis, intracellular calcium overload, and contractile 
dysfunction.16 Results of early studies suggested that ranola-
zine improved myocardial energy metabolism by reducing 
fatty acid  oxidation and increasing glucose oxidation.17 
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However, these effects require relatively high concentra-
tions of ranolazine, whereas improvement in cardiac func-
tion and clinical status occur in the presence of much lower 
concentrations.18
In recent years, the research focus has shifted toward 
INaL as a contributor to the pathogenesis of angina.19,20 
 Activation of cardiac myocytes in normal hearts leads 
to rapid cell depolarization (the upstroke of the action 
potential) through brief opening of membrane sodium 
channels (INa). Most sodium channels are inactivated 
within a few  milliseconds, but a few may continue to 
open and close spontaneously during the action potential 
plateau for reasons that are not understood. This current 
has been referred to as INaL. Under normal conditions, 
INaL constitutes only 1% of peak INa. Voltage-dependent 
calcium channels then open and initiate a large outflow 
of sarcoplasmic calcium into the cytoplasm, initiating 
myocardial contraction through the coupling of actin and 
myosin filaments.19–21
Several pathological conditions, including ischemia and 
heart failure, can significantly increase the late component 
of the sodium channel current.22,23 This may be followed by 
increases in myocyte membrane sodium calcium exchange, 
resulting intracellular increases of calcium, and excessive 
calcium loading of the sarcoplasmic reticulum. Calcium 
overload of myocardial cells is associated with electrical 
instability, increased diastolic and reduced systolic force 
generation, and an increase in oxygen consumption.24 The 
increase in diastolic tension may cause compression of 
the vascular space and further reduction of blood flow and 
 oxygen delivery (Figure 1).25–27
Ranolazine has been shown to selectively inhibit INaL in 
canine and pig models without affecting the fast sodium cur-
rent responsible for the upstroke of the action potential.12–28 
The effect of ranolazine on INaL is more pronounced 
in ischemic or failing myocytes in which the current is 
 amplified. Therefore, ranolazine has the potential to disrupt 
the  consequences of myocardial ischemia by reducing excess 
sodium influx, reducing calcium overload, and the noxious 
increase in left ventricular wall tension.
Further, ranolazine significantly inhibits the rapidly acti-
vating component of the delayed rectifier or IKr. Although 
inhibition of IKr by ranolazine prolongs the action potential 
duration, inhibition of INaL and the late ICa2+ (which is 
also affected) shorten the duration of the action potential 
such that the net effect on its duration, or QTc, is usually 
modest (Figure 2).12 Experimental and clinical studies have 
shown that ranolazine has antiarrhythmic effects in both the 
ventricles and atria.13
Use of ranolazine in chronic  
stable angina
The eff icacy of ranolazine in CSA patients has been 
demonstrated in several randomized trials. Early trials 
used the immediate-release formulation administered three 
times daily and failed to show superior antianginal and anti-
 ischemic effects over placebo.29,30 Subsequently, the ER ver-
sion was tested in several clinical studies, the major results 
of which are summarized in Table 1.
MARISA (Monotherapy Assessment of Ranola-
zine In Stable Angina) was a randomized, multicenter, 
double-blind, dose-finding study utilizing ranolazine ER 
as monotherapy for angina.31 A total of 191 patients with 
documented coronary artery disease and exercise-limiting 
angina were enrolled. Existing antianginal treatment (with 
the exception of sublingual nitroglycerin) was discontinued 
prior to randomization. Ranolazine ER at doses of 500 
mg, 1,000 mg, and 1,500 mg or placebo, was administered 
twice daily for one week in this four-period crossover study. 
Exercise  treadmill tests were performed at the end of each 
study period to coincide with peak (4 hours) and trough 
(12 hours) plasma levels. Compared with placebo, ranolazine 
demonstrated significant dose-dependent improvements in 
Disease(s) and pathological states linked to imbalance of O2
supply/demand
INaL
Na+-entry ([Na+]i)
Cytosolic Ca2+
Electrical instability
• Afterpotentials
• Beat-to-beat APD
• Arrhythmias (VT)
Mechanical dysfunction
• Abnormal contraction
  and relaxation
• Diastolic tension
NCX
Figure 1 increase in intracellular sodium concentration ([Na+]i) in pathological 
conditions linked to imbalances between oxygen supply and demand causes calcium 
entry through the Na+/Ca2+ exchanger (NCX). 
Notes: An enhanced late sodium current (INaL) contributes to [Na+]
i-dependent calcium overload, leading to electrical instability and mechanical 
dysfunction. Copyright © 2006, BMJ Publishing Group Ltd. Reproduced from 
Belardinelli L, Shryock JC, Fraser H. inhibition of the late sodium current as a 
potential cardioprotective principle: effects of the late sodium current inhibitor 
ranolazine. Heart. 2006;92(Suppl 4):iv6–iv14, with permission from BMJ Publishing 
Group Ltd.20
Abbreviations: APD, action potential duration; VT, ventricular tachycardia.
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total exercise duration, time to angina, and time to 1 mm 
ST-segment depression at both peak and trough levels, with 
minimal effects on heart rate and blood pressure. Safety of 
the drug was also studied in this trial, with some patients 
continuing in an open-label, observational follow-on study. 
One-year survival in this group was in line with the pre-
dicted rate.
Overall, the drug was well tolerated, with less than 8% of 
patients discontinuing ranolazine because of adverse effects. 
The majority of these patients were on the 1,500 mg dose, 
which was related to higher rates of dizziness, nausea, asthe-
nia, and constipation. Dose-related increases in the corrected 
QT interval were also noted, although this was not a reason 
for drug discontinuation. Thus, the MARISA study demon-
strated that ranolazine was effective and safe as monotherapy 
for angina. The optimum risk to benefit ratio was noted 
in the lower doses, with the authors suggesting starting at 
500 mg and titrating upwards to 750 mg or 1,000 mg twice 
daily as needed to achieve angina control. In contemporary 
clinical practice, ranolazine is not used as the sole antianginal 
agent, making the above findings less applicable to current 
patients.
In contrast with MARISA, the CARISA  (Combination 
Assessment of Ranolazine In Stable Angina) trial was 
intended to evaluate the efficacy of ranolazine ER when used 
in conjunction with standard doses of typical  antianginal 
drugs (atenolol 50 mg/day, diltiazem 180 mg/day, or 
 amlodipine 5 mg/day), prescribed based on physician 
discretion.32 This was a much larger multicenter interna-
tional trial, randomizing 823 patients with severe chronic 
angina to receive ranolazine ER 750 mg or 1,000 mg twice 
daily, or placebo (with background antianginal therapy for 
all patients) for 12 weeks in a three-group, parallel, double-
blind design. Treadmill exercise testing at peak and trough 
plasma levels was performed after 2, 6 (trough only), and 
12 weeks of treatment. Increase in trough symptom-limited 
exercise duration (the primary endpoint) was significantly 
greater in both ranolazine groups compared with placebo. 
The time to onset of angina at trough and peak plasma 
concentrations was also greater with ranolazine. The time 
to $1 cm ST-segment depression at peak concentration 
was longer than with placebo in both ranolazine arms, 
although the same parameter at trough concentrations did 
not significantly differ between the two doses of ranolazine 
tested. Frequency of angina attacks and nitroglycerin use 
were significantly reduced in both ranolazine groups, and 
like in the MARISA trial, these benefits were noted in the 
absence of any significant hemodynamic effects. Impor-
tantly, treatment with other antianginals did not blunt the 
response to ranolazine.
Several subgroup analyses of this trial were reported. 
Among 258 patients considered to be treated with 
0 0
Late
Peak
Late
Peak
Sodium current
(nA)
Action potential
(mV)
Twitch
Time (msec) Time (msec)
Figure 2 Relation between peak and late sodium current and ventricular action potential (AP) and contraction.
Notes: INaL is the current associated with the slow inactivating component of the INa (sodium channel). Panels A and B illustrate a normal and an increased INa (due 
to impaired inactivation of the Na+ channel), respectively. The enhanced late INa is accompanied by delayed ventricular repolarization (long APs and occasional early 
afterdepolarizations) and abnormal twitch (contraction composed of a phasic and a tonic component). Copyright © 2004, Oxford University Press. Reproduced from 
Belardinelli L, Antzelevitch C, Fraser H, inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium dependent calcium 
overload and its detrimental effects on cardiomyocyte function, European Heart Journal, 2004;6(Suppl i):i3–i7, by permission of Oxford University Press.23
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maximally tolerated doses of beta-blockers or cal-
cium channel blockers (based on the parameters of 
systolic blood  pressure #100 mmHg, a resting heart 
rate #60 beats per minute, and/or an electrocardiographic 
PR  interval $200 msec) ranolazine improved exercise 
 tolerance at both trough and peak concentrations, along 
with significant lengthening in the times to angina onset 
and $1 mm  ST-segment depression at peak but not trough 
concentrations. Consistent significant reductions were also 
noted in frequency of angina and nitroglycerin consumption.33 
 Similarly, when patients with diabetes (n=189) were studied 
separately, there was no significant interaction with respect to 
the benefits of ranolazine on symptom-limited or ischemia-
limited exercise duration, angina frequency, or nitroglycerin 
use.34  Additionally, in 237 patients with New York Heart 
 Association class I or II heart failure, the effects of ranolazine 
ER on improving exercise tolerance prevailed.35
Overall, treatment was well tolerated at both doses. 
Adverse events were reported in 31.2% and 32.7% of 
ranolazine ER 750 mg and 1,000 mg recipients, respectively, 
compared with 26.4% of placebo-treated patients. Constipa-
tion,  dizziness, nausea, and asthenia were most commonly 
reported. Five patients in the ranolazine ER 1,000 mg arm 
experienced syncope without evident ventricular tachyar-
rhythmia, although significant dose-related increases in the 
corrected QT interval were seen with both doses of ranolazine. 
Among the 750 ranolazine-treated patients who continued on 
to an  open-label, observational follow-on study, survival rates 
of 98.4% and 95.9% after 1 or 2 years of follow-up, respec-
tively, were reported, and were similar to expected rates. Thus, 
there was no long-term signal of significant harm.
The ROLE (Ranolazine Open Label Experience) program 
included 746 patients who completed the MARISA and CAR-
ISA trials and consented to participate in an open-label, 6-year 
follow-on extension.36 After 2.8 years of follow-up, 9.7% dis-
continued ranolazine due to adverse events, with age $64 years 
being the only predictor of drug discontinuation. Mean QTc 
interval was prolonged by a statistically significant 2.4 msec, 
although this did not lead to any discontinuations or reported 
torsades de pointes. Annual mortality was reported at 2.8% 
compared with .5% as predicted by the Duke Treadmill Score. 
Thus, long-term therapy with ranolazine appeared to be well 
tolerated, with no indication of a higher than predicted mortal-
ity in this population with stable ischemic heart disease.
The objective of the ERICA (Efficacy of Ranolazine In 
Chronic Angina) trial was to specifically examine the anti-
anginal efficacy of ranolazine when used with maximum rec-
ommended doses of amlodipine.37 In this study, 565 patients 
with three or more episodes of chronic stable angina per week, 
despite receiving amlodipine 10 mg/day, were randomized to 
additional treatment with ranolazine ER 1,000 mg or placebo 
twice daily for 6 weeks. Patients were allowed to be on long-
acting nitrates, but not on beta-blockers. Compared with 
placebo, ranolazine significantly reduced the weekly average 
frequency of self-reported angina episodes (primary endpoint) 
and nitroglycerin use. The therapeutic effect appeared to be 
more prominent in those with more severe baseline angina. 
In particular, significant reductions in nitroglycerin use and 
Seattle Angina Questionnaire angina frequency were observed 
for patients with more than 4.5 anginal episodes per week, 
but only in angina frequency for those with less frequent 
baseline symptoms.
Overall, ranolazine remained well tolerated and did not 
cause any notable change in hemodynamic parameters. 
 Compared with 35.3% of placebo recipients, 39.9% of 
 ranolazine ER recipients reported adverse events, mostly of 
mild to moderate severity. Again, constipation was  commonly 
reported, in addition to peripheral edema, dizziness, nausea, 
and headache. Therefore, the ERICA trial confirmed the 
incremental antianginal effect of ranolazine in addition to 
maximal-dose amlodipine.
Data from CARISA and ERICA were pooled to compare 
endpoints between patients aged $70 years (n=363) and 
those ,70 years of age (n=1,024). The efficacy of ranolazine 
remained similar in both age groups, although nonserious 
adverse effects were more common in the elderly.38 Patient 
information from two additional trials, MARISA and an early 
trial comparing ranolazine to atenolol,30,31 was added to study 
outcomes among women. Overall, data from these four trials 
demonstrated that the favorable effects of ranolazine were 
somewhat diminished in women, with less improvement than 
men in exercise testing, but similar improvements in angina 
frequency, nitroglycerin  consumption, and Seattle Angina 
Questionnaire angina frequency scores.39
Recently, the TERISA (Type 2 Diabetes Evaluation of 
Ranolazine in Subjects With Chronic Stable Angina) trial 
was completed to evaluate the performance of ranolazine in 
patients with diabetes, coronary artery disease, and CSA.40 
After a single-blind, 4-week placebo run-in, 949 patients 
(on one or two antianginal medications) were randomized 
to treatment with ranolazine ER 1,000 mg twice daily or 
placebo. After 8 weeks, the average weekly number of angina 
episodes (primary endpoint) was significantly reduced in the 
ranolazine-treated arm compared with placebo, as was the 
need for sublingual nitroglycerin. Therefore, ranolazine was 
proven to retain significant benefits among diabetic patients, 
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although the overall magnitude of effects was somewhat 
diminished compared with previous studies.
Ranolazine in acute coronary  
syndromes
The randomized, double-blind, multinational MERLIN 
(Metabolic Efficiency with Ranolazine for Less Ischemia 
in Non-ST-Elevation Acute Coronary Syndrome)-TIMI 
(Thrombolysis In Myocardial Infarction) 36 trial was 
designed to examine the safety and efficacy of ranolazine in 
an acute coronary syndrome population already receiving 
conventional treatment.41 In all, 6,560 patients were random-
ized within 48 hours of angina onset to additionally receive 
ranolazine (intravenously for the first 96 hours and then 
orally 1,000 mg ER twice daily), or placebo for a median of 
348 days. Although no beneficial effect of ranolazine was 
noted on the composite of cardiovascular death, myocardial 
infarction, or recurrent ischemia (primary efficacy endpoint), 
the incidence of recurrent ischemia alone was significantly 
lower in the ranolazine group, as was the rate of worsening 
angina requiring intensification of medical therapy.42 Mean 
Seattle Angina Questionnaire scores for angina frequency 
(at 4 and 12 months), quality of life, and treatment satisfac-
tion (at 12 months) were significantly improved with rano-
lazine ER than with placebo.43 Similar to the overall trial 
results, the risk of recurrent ischemia, worsening angina, and 
intensification of antianginal therapy were all significantly 
reduced in patients with prior CSA. In the subgroup of CSA 
patients evaluated by exercise treadmill testing at 8 months, 
the mean total exercise duration and times to onset of angina 
or $1 mm ST-segment depression were significantly greater 
with ranolazine ER, consistent with prior studies.
Improvements in several domains of patient-reported 
angina-related health status and quality of life were seen 
with ranolazine ER in these CSA patients. Of note, among 
patients without CSA prior to their acute event, no such sig-
nificant treatment effects were reported. Another subgroup 
analysis in those who underwent percutaneous coronary 
intervention within 30 days of randomization, showed a 27% 
reduction in the composite primary endpoint, driven by sig-
nificant reductions in recurrent ischemia and cardiovascular 
death. Recurrent ischemia and recurrent ischemia requiring 
repeat revascularization were also significantly reduced.
Based on these findings, RIVER-PCI (Ranolazine for 
Incomplete Vessel Revascularization Post–Percutaneous 
 Coronary Intervention), a randomized, double-blind, Phase III, 
international study of approximately 2,600 participants, is 
currently ongoing to evaluate the efficacy of ranolazine in 
reducing ischemia-driven revascularization or hospitalization 
in patients with CSA and incomplete revascularization after 
percutaneous coronary intervention.44
As the MERLIN-TIMI 36 trial enrolled a higher risk 
cohort in comparison with previous trials among stable isch-
emic heart disease patients, special attention was paid to the 
safety of ranolazine. Overall, all-cause mortality (at 6, 12, 
or 18 months) was similar in the ranolazine and placebo 
groups, as was the incidence of death or any cardiovascular 
hospitalization, or sudden cardiac death. The incidence of 
symptomatic documented arrhythmias over the duration of 
the study was also similar, although clinically significant 
arrhythmias were observed less frequently during Holter 
monitoring in the first 7 days with ranolazine group versus 
placebo. Adverse events leading to discontinuation of medi-
cation were significantly more common in the ranolazine 
group (8.1% versus 4.1% for placebo), with dizziness, 
nausea, and constipation being most commonly reported. 
Unfortunately, there are not much data regarding the safety 
of ranolazine in special populations, especially the elderly. 
In summary, no significant benefit of ranolazine compared 
with placebo was seen in this trial of patients with non-ST-
segment elevation acute coronary syndrome with respect to 
the primary efficacy endpoints, although ranolazine appeared 
to be relatively safe and well tolerated.
Role of ranolazine in patients  
with diastolic dysfunction
Considering its effect on the INaL, ranolazine could 
 potentially affect diastolic function by promoting calcium 
extrusion through the sodium calcium exchanger, thus improv-
ing diastolic tension and relaxation. A study by Figueredo 
et al assessed echocardiographic parameters of systolic and 
diastolic function before and 2 months after initiation of 
ranolazine in 22 patients with CSA. There were significant 
improvements in global left ventricular function, as assessed 
by myocardial performance index and diastolic function in 
patients who received ranolazine.45 More recently, the RALI-
DHF (RAnoLazIne for the  Treatment of Diastolic Heart 
Failure) study was published.46 This was a small, prospective, 
randomized, double-blind, placebo-controlled, proof-of-con-
cept study of 20 patients with symptoms of congestive heart 
failure, preserved left ventricular ejection fraction (.45%), 
and laboratory, echocardiographic, or hemodynamic evi-
dence of elevated filling pressures.  Treatment consisted of 
intravenous infusion of ranolazine for 24 hours, followed by 
oral treatment for 13 days versus  placebo. Left ventricular 
end-diastolic pressure and pulmonary capillary wedge pres-
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sure decreased in the ranolazine group, but not in the placebo 
group. After 14 days of treatment, no significant changes were 
observed in echocardiographic or  cardiopulmonary exercise 
test parameters. Thus, this study failed to provide evidence 
of any substantial expected clinical benefit from ranolazine 
in this specific population.
Ranolazine as an  
antiarrhythmic agent
The fairly selective blocking effect of the late sodium current 
led to the investigation of ranolazine as a novel antiarrhythmic 
agent.13–47 In a secondary analysis of the MERLIN-TIMI 36 
trial, ranolazine was associated with significant reductions 
in supraventricular tachyarrhythmias (P,0.001) as well as 
a 30% reduction in new-onset atrial fibrillation (P,0.08).48 
Small studies have suggested a role for ranolazine as a 
potential treatment for atrial fibrillation, facilitating  electrical 
cardioversion in cardioversion-resistant patients, and as a 
potential “pill-in-the-pocket” approach.49–51 Additionally, 
one study showed a potential synergistic effect between 
 ranolazine and dronedarone for suppressing arrhythmia.52 
In an observational study by Miles et al, ranolazine was 
found to be more effective than amiodarone in preventing 
 postoperative atrial fibrillation (15% versus 25%).53 Based on 
these findings, there are two large randomized clinical trials, 
ie, RAFFAELLO (Ranolazine in Atrial Fibrillation  Following 
An ELectricaL CardiOversion), currently  underway 
examining the efficacy of ranolazine in maintaining sinus 
rhythm in patients with atrial fibrillation, and HARMONY 
(A Study to Evaluate the Effect of Ranolazine and Drone-
darone When Given Alone and in Combination in Patients 
With Paroxysmal Atrial Fibrillation).54,55
In the future, ranolazine may become an alternative option 
for treatment of ventricular arrhythmias. Data from continu-
ous electrocardiographic monitoring in the MERLIN-TIMI 
36 study showed that ranolazine significantly suppressed 
episodes of ventricular tachycardia of more than eight beats 
(P,0.001).48 In a small size, nonrandomized study, Bunch et al 
analyzed data from 12 patients with ventricular tachycardia 
refractory to antiarrhythmic drugs. Ranolazine proved effective 
in reducing ventricular tachycardia burden and shocks from 
implantable cardioverter defibrillators.56 Of note, the mean 
QRS and the QTc interval increased nonsignificantly.
In patients with LQT3 (long QT syndrome type 3), 
a monogenic disorder in which the electrophysiological 
 phenotype is due to an increase in INaL, ranolazine has 
been shown to cause a dose-dependent abbreviation of the 
QTc.57 Lastly, a study of eight patients with symptomatic 
premature ventricular complexes (PVCs) with a minimum 
PVC  burden .10% on 24-hour Holter monitoring received 
ranolazine which resulted in a median decrease in PVC bur-
den of 60.2% (P=0.06).58 These findings are supportive of 
further studies specifically designed to address the hypothesis 
that ranolazine has antiarrhythmic effects in the ventricle.
Cost-effectiveness
Several cost-effectiveness analyses have been performed, with 
results favoring greater use of ranolazine. In one study utiliz-
ing a large US commercial insurance claims database, cost 
comparisons were made between three groups of patients, 
ie, those on long-acting nitrates, those on beta-blockers or 
calcium channel blockers, and those on ranolazine. After the 
index event (ie, change in antianginal therapy), ranolazine 
users had lower revascularization rates than the other groups, 
leading to significantly lower total costs of care.59
Another study examined the cost-effectiveness of adding 
ranolazine to standard-of-care antianginal therapy in patients 
experiencing three or more attacks per week. The incremental 
cost-effectiveness ratio for one patient for the addition of 
ranolazine was $32,682 per quality-adjusted life year (QALY), 
which is less than the $50,000 per QALY  traditionally consid-
ered to be the threshold for cost-effectiveness.60 Finally, in a 
European study, the cost-utility of ranolazine versus placebo 
was computed as an add-on therapy for symptomatic chronic 
angina pectoris. The incremental cost-utility ratio was 8,455 
Euros per QALY per patient, which is considerably less than 
the conventional willingness-to-pay threshold of 15,000 Euros 
per QALY.61 In summary, ranolazine therapy appears to be 
cost-effective over a variety of health care systems, likely by 
reducing angina-related hospitalization and  revascularization, 
and improving quality of life.
Conclusion
Ranolazine is a relatively new agent added to the limited 
armamentarium for treatment of CSA. Its lack of significant 
impact on blood pressure and heart rate make it an attractive 
drug to utilize in different clinical scenarios. In recent years, 
multiple, randomized, placebo-controlled clinical trials 
have confirmed its benefit in patients with CSA, improving 
functional capacity and decreasing anginal episodes. At this 
time, there is no clear evidence in favor of using ranolazine 
in the treatment of acute coronary syndromes, as shown in 
MERLIN-TIMI 36. Also, there are not sufficient data to 
recommend its use for patients with congestive heart failure. 
On the other hand, its effect on the INaL is quite promising 
for the electrophysiology community, as some evidence 
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exists that ranolazine can decrease the incidence of atrial 
fibrillation and ventricular tachyarrhythmias. In summary, 
ranolazine appears to be a drug with an acceptable safety 
profile, a clear role in the treatment of CSA, and significant 
potential for use in patients with arrhythmias.
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